Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study

References

• AIM-HIGH trial, http://www.clinicaltrials.gov identifier NCT00120289
   Google Scholar
• Al-SheikhAAKarasRHRelative safety of lipid altering drugs in the general population2005Abstract 3707, presented at the 2005. American Heart Association Scientific SessionsNov 13–6, 2005Dallas, Texas, USA
   Google Scholar
• AssmannGSchulteHvon EckardsteinAHigh-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transportAtherosclerosis1996124Supp lS11208831911
   PubMedGoogle Scholar
• BalkauBCharlesMADrivsholmTFrequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndromeDiabetes Metab2002283647612461473
   PubMed Web of Science ®Google Scholar
• BaysHEDujovneCAMcGovernMEComparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE])Am J Cardiol2003916677212633795
   PubMed Web of Science ®Google Scholar
• BaysHEMcGovernMEOnce-daily niacin extended release/lovastatin combination tablet has more favorable effects on lipoprotein particle size and subclass distribution than atorvastatin and simvastatinPrev Cardiol200361798814605511
   PubMedGoogle Scholar
• BrownBGZhaoX-QChaitASimvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary diseaseN Engl J Med200134515839211757504
   PubMed Web of Science ®Google Scholar
• BrownGAlbersJJFisherLDRegression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein BN Engl J Med19903231289982215615
   PubMed Web of Science ®Google Scholar
• BruckertEBaccara-DinetMMcCoyFHigh prevalence of low HDL-cholesterol in a pan-European survey of 8545 dyslipidaemic patientsCurr Med Res Opin2005a2119273416368042
   PubMed Web of Science ®Google Scholar
• BruckertEPamphileRMcCoyFDefining the prevalence of low HDL-C in a European cohort of dyslipidaemic patientsEuropean Heart J Suppl2005bF236
   Web of Science ®Google Scholar
• BruckertEBaccara-DinetMEschwegeELow HDL-cholesterol is highly prevalent among European type 2 diabetes patients receiving treatment for dyslipidaemia: data from a pan-European surveyDiabet Med2007In press
   PubMed Web of Science ®Google Scholar
• CannerPLBergeKGWengerNKFifteen-year mortality in Coronary Drug Project patients: long-term benefit with niacinJ Am Coll Cardiol198681245553782631
   PubMed Web of Science ®Google Scholar
• CannerPLFurbergCDTerrinMLBenefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project)Am J Cardiol200595254715642562
   PubMed Web of Science ®Google Scholar
• CannerPLFurbergCDMcGovernMEBenefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project)Am J Cardiol200697477916461040
   PubMed Web of Science ®Google Scholar
• CapuzziDMGuytonJRMorganJMEfficacy and safety of an extended-release niacin (Niaspan): a long-term studyAm J Cardiol19988274U81U
   PubMed Web of Science ®Google Scholar
• Cashin-HemphillLMackWJPogodaJMBeneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-upJAMA1990264301372243429
   PubMed Web of Science ®Google Scholar
• CastelliWPGarrisonRJWilsonPWIncidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham StudyJAMA1986256283583773200
   PubMed Web of Science ®Google Scholar
• CastelliWPCholesterol and lipids in the risk of coronary artery disease—the Framingham Heart StudyCan J Cardiol19884Suppl A5A10A3282627
   PubMed Web of Science ®Google Scholar
• [CDP] Coronary Drug Project Research GroupClofibrate and niacin in coronary heart diseaseJAMA1975231360811088963
   PubMed Web of Science ®Google Scholar
• ChapmanMJHow does nicotinic acid modify the lipid profile?Eur Heart J Suppl20068F549
   Web of Science ®Google Scholar
• DaltonTABerryRSHepatotoxicity associated with sustained-release niacinAm J Med19929310241626557
   PubMed Web of Science ®Google Scholar
• DominguezLJGaliotoAFerlisiAAgeing lifestyle modifications and cardiovascular disease in developing countriesJ Nutr Health Aging200610143916554951
   PubMed Web of Science ®Google Scholar
• DrexelHAczelSMarteTIs atherosclerosis in diabetes and impaired fasting glucose driven by elevated LDL cholesterol or by decreased HDL cholesterol?Diabetes Care200528101715616241
   PubMed Web of Science ®Google Scholar
• DubeMPWuJWAbergJASafety and efficacy of extended-release niacin for the treatment of dyslipidaemia in patients with HIV infection: AIDS Clinical Trials Group Study A5148Antivir Ther2006111081917302378
   PubMed Web of Science ®Google Scholar
• Expert Panel on Detection Evaluation, and Treatment of High Blood Cholesterol in AdultsExecutive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)JAMA200128524869711368702
   PubMed Web of Science ®Google Scholar
• FordESGilesWHDietzWHPrevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination SurveyJAMA2002287356911790215
   PubMed Web of Science ®Google Scholar
• FrickMHEloOHaapaKHelsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors and incidence of coronary heart diseaseN Engl J Med19873171237453313041
   PubMed Web of Science ®Google Scholar
• GoldbergAAlagonaPJrCapuzziDMMultiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemiaAm J Cardiol2000851100510781759
   PubMed Web of Science ®Google Scholar
• GoldbergIJClinical review 124: Diabetic dyslipidemia: causes and consequencesJ Clin Endocrinol Metab2001869657111238470
   PubMed Web of Science ®Google Scholar
• GoldbourtUYaariSMedalieJHIsolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 menArterioscler Thromb Vasc Biol199717107139012644
   PubMed Web of Science ®Google Scholar
• GordonDJProbstfieldJLGarrisonRJHigh-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studiesCirculation1989798152642759
   PubMed Web of Science ®Google Scholar
• GordonTCastelliWPHjortlandMCHigh density lipoprotein as a protective factor against coronary heart disease. The Framingham StudyAm J Med19776270714193398
   PubMed Web of Science ®Google Scholar
• GrundySMVegaGLMcGovernMEEfficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the Assessment of Diabetes Control and Evaluation of the Efficacy of Niaspan TrialArch Intern Med200216215687612123399
   PubMed Web of Science ®Google Scholar
• GrundySMVegaGLMcGovernMEComparative effects on lipids and glycemic control of niacin extended-release/lovastatin or fenofibrate in patients with diabetic dyslipidemiaAbstract 29-LB, presented at the 64th Scientific Sessions of the American diabetes AssociationJune 4-8 2004Orlando, Florida, USA
   Google Scholar
• GuytonJRCapuzziDMTreatment of hyperlipidemia with combined niacin-statin regimensAm J Cardiol19988282U84U9671014
   PubMed Web of Science ®Google Scholar
• HanselBGiralPNobecourtEMetabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activityJ Clin Endocrinol Metab20048949637115472192
   PubMed Web of Science ®Google Scholar
• HodisHNMackWJLaBreeLThe role of carotid arterial intima-media thickness in predicting clinical coronary eventsAnn Intern Med199812826299471928
   PubMed Web of Science ®Google Scholar
• HunninghakeDBMcGovernMEKorenMA dose-ranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatinClin Cardiol200326112812685616
   PubMed Web of Science ®Google Scholar
• InsullWMcGovernMESchrottHEfficacy of extended-release niacin with lovastatin for hypercholesterolemia assessing all reasonable doses with innovative surface graph analysisArch Intern Med20041641121715159270
   PubMed Web of Science ®Google Scholar
• IsomaaBAlmgrenPTuomiTCardiovascular morbidity and mortality associated with the metabolic syndromeDiabetes Care200124683911315831
   PubMed Web of Science ®Google Scholar
• KaneJPMalloyMJPortsTARegression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimensJAMA19902643007122243428
   PubMed Web of Science ®Google Scholar
• KashyapMLMcGovernMEBerraKLong-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemiaAm J Cardiol199889672811897208
   PubMedGoogle Scholar
• KasteleinJJPThe realities of dyslipidaemia: what do the studies tell us?Eur Heart J Suppl20057F2733
   Web of Science ®Google Scholar
• KeechASimesRJBarterPEffects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trialLancet200536618496116310551
   PubMed Web of Science ®Google Scholar
• KnoppRHAlagonaPDavidsonMEquivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemiaMetabolism19984710971049751239
   PubMed Web of Science ®Google Scholar
• McGovernMEMalottCMSimmonsPDOnce-daily niacin-extended-release/lovastatin combination is effective and safe for treatment of dyslipidaemia associated with metabolic syndromeAbstract 820–5 Scientific session of the American College of Cardiology2004
   Google Scholar
• McKenneyJMJonesPHBaysHEComparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study)Atherosclerosis2007 Epub ahead of print
   PubMed Web of Science ®Google Scholar
• MillerNEHammettFSaltissiSRelationship of angiographically defined coronary artery disease to plasma lipoprotein subfractions and apolipoproteinsBr Med J1981282174146786600
   PubMed Web of Science ®Google Scholar
• MorganJMCapuzziDMBakshRIEffects of extended-release niacin on lipoprotein subclass distributionAm J Cardiol2003911432612804729
   PubMed Web of Science ®Google Scholar
• MorganJMCapuzziDMGuytonJRTreatment effect of Niaspan, a controlled-release niacin, in patients with hypercholesterolemia: a placebo-controlled trialJ Cardiovasc Pharmacol Ther1996119520210684417
   PubMedGoogle Scholar
• NiskanenLTurpeinenAPenttilaIHyperglycemia and compositional lipoprotein abnormalities as predictors of cardiovascular mortality in type 2 diabetes: a 15-year follow-up from the time of diagnosisDiabetes Care199821186199802734
   PubMed Web of Science ®Google Scholar
• PieperJAUnderstanding niacin formulationsAm J Manag Care20028Suppl 12S3081412240702
   PubMed Web of Science ®Google Scholar
• PocockSJShaperAGPhillipsANConcentration of high density lipoprotein cholesterol, triglycerides, and total cholesterol in ischaemic heart diseaseBr Med J198929899810022499392
   PubMed Web of Science ®Google Scholar
• RaymondSULeederSGreenbergHMObesity and cardiovascular disease in developing countries: a growing problem and an economic threatCurr Opin Clin Nutr Metab Care20069111616477174
   PubMed Web of Science ®Google Scholar
• RobinsonJGDavidsonMHCombination therapy with ezetimibe and simvastatin to achieve aggressive LDL reductionExpert Rev Cardiovasc Ther200644617616918265
   PubMedGoogle Scholar
• RubinsHBRobinsSJCollinsDGemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study GroupN Engl J Med1999341410810438259
   PubMed Web of Science ®Google Scholar
• SharrettARBallantyneCMCoadySACoronary heart disease prediction from lipoprotein cholesterol levels triglycerides lipoprotein(a), apolipoproteins A-I and B and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) StudyCirculation200110411081311535564
   PubMed Web of Science ®Google Scholar
• SweetDEMetabolic complications of antiretroviral therapyTop HIV Med20051370416082057
   PubMedGoogle Scholar
• TaylorAJLeeHJSullenbergerLEThe effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3Curr Med Res Opin20062222435017076985
   PubMed Web of Science ®Google Scholar
• TaylorAJSullenbergerLELeeHJArterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statinsCirculation20041103512715537681
   PubMed Web of Science ®Google Scholar
• Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts)European guidelines on cardiovascular disease prevention in clinical practiceEur J Cardiovasc Prev Rehabil200310S1S1014555889
   PubMedGoogle Scholar
• TurnerRCMillnsHNeilHARisk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23)BMJ199831682389549452
   PubMed Web of Science ®Google Scholar
• VanJTPanJWastyTComparison of extended-release niacin and atorvastatin monotherapies and combination treatment of the atherogenic lipid profile in diabetes mellitusAm J Cardiol2002891306812031735
   PubMed Web of Science ®Google Scholar
• VogtAKassnerUHostalekUEvaluation of the safety and tolerability of prolonged-release nicotinic acid in a usual care setting: the NAUTILUS studyCurr Med Res Opin2006a224172516466614
   PubMed Web of Science ®Google Scholar
• VogtAKassnerUHostalekUNAUTILUS (safety and tolerability of Niaspan®): a subgroup analysis of patients with diabetesBr J Diabetes Vasc Dis2006b612733
   Google Scholar
• VogtAKassnerUHostalekUSafety and tolerability of prolonged-release nicotinic acid in patients aged >65 years enrolled in NAUTILUSBr J Cardiol2006c1327882
   Google Scholar
• VogtAKassnerUHostalekUSafety and tolerability of prolonged-release nicotinic acid combined with a statin in NAUTILUSBr J Cardiol2006d132737
   Google Scholar
• WhitneyEJKrasuskiRAPersoniusBEA randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical eventsAnn Intern Med20051429510415657157
   PubMed Web of Science ®Google Scholar
• WilsonPWAbbottRDCastelliWPHigh density lipoprotein cholesterol and mortality. The Framingham Heart StudyArteriosclerosis19888737413196218
   PubMedGoogle Scholar
• WolfeMLVartanianSFRossJLSafety and effectiveness of niaspan when added sequentially to a statin for treatment of dyslipidemiaAm J Cardiol200187476911179541
   PubMed Web of Science ®Google Scholar
• YusufSHawkenSOunpuuSEffect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control studyLancet20043649375215364185
   PubMed Web of Science ®Google Scholar